After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...
Clinical Trials Arena on MSN
Keenova seeks Xiaflex expansion on late-stage rare disease win
If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...
MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his ...
Endo is ramping up the next phase of its Dupuytren's contracture marketing drive. Not long after running its first branded ad for Xiaflex in the indication, the drugmaker has dubbed September the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results